可注射水凝胶递送IL-2减少NOD小鼠自身免疫性糖尿病发生
该研究利用肝素、胶原和透明质酸聚合物构建可注射水凝胶递送IL-2,在NOD小鼠中评估其缓释能力及预防自身免疫性糖尿病的效果。结果显示水凝胶体外和体内均持续释放IL-2约12天,肝素结合增强IL-2活性并促进FOXP3+调节性T细胞扩增;每周注射含IL-2水凝胶可部分预防自身免疫性糖尿病,而可溶性IL-2注射无效。
要点
- 水凝胶在体外和体内均持续释放IL-2约12天。
- 肝素结合增强IL-2活性并促进FOXP3+ Treg扩增。
- 每周注射含IL-2水凝胶可部分预防NOD小鼠自身免疫性糖尿病。
核心结论
- 可注射水凝胶递送IL-2可能减少自身免疫性糖尿病IL-2治疗方案所需的注射次数。
研究设计与样本
- 在NOD小鼠1型糖尿病模型中比较可溶性IL-2与经水凝胶递送IL-2注射预防自身免疫性糖尿病的效果。
- 水凝胶由临床级肝素、胶原和透明质酸聚合物构成,利用肝素的IL-2结合能力递送IL-2。
- 检测该材料的IL-2释放动力学与体内稳定性。
主要发现
- 体外观察到水凝胶在12天时间内释放IL-2,注射后水凝胶在体内同样持续存在12天。
- 肝素结合增强IL-2活性,并增强IL-2和TGFβ介导的FOXP3+ Treg扩增。
- 每周给予含IL-2水凝胶部分预防自身免疫性糖尿病,而可溶性IL-2注射未显示该效果。
临床怎么用
- 结果提示水凝胶递送有望减少自身免疫糖尿病IL-2治疗方案的注射频次,但仍需进一步临床验证。
局限性
- 研究为NOD小鼠模型,结论外推至人类需谨慎。
- 原文未报告具体样本量、P值及效应量等统计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: IL-2 injections are a promising therapy for autoimmune type 1 diabetes but the short half-life of this cytokine in vivo limits effective tissue exposure and necessitates frequent injections. Here we have investigated whether an injectable hydrogel could be used to promote prolonged IL-2 release in vivo. METHODS: Capitalising on the IL-2-binding capabilities of heparin, an injectable hydrogel incorporating clinical-grade heparin, collagen and hyaluronan polymers was used to deliver IL-2. The IL-2-release kinetics and in vivo stability of this material were examined. The ability of soluble IL-2 vs hydrogel-mediated IL-2 injections to prevent autoimmune diabetes in the NOD mouse model of type 1 diabetes were compared. RESULTS: We observed in vitro that the hydrogel released IL-2 over a 12-day time frame and that injected hydrogel likewise persisted 12 days in vivo. Notably, heparin binding potentiates the activity of IL-2 and enhances IL-2- and TGFβ-mediated expansion of forkhead box P3-positive regulatory T cells (FOXP3+ Tregs). Finally, weekly administration of IL-2-containing hydrogel partially prevented autoimmune diabetes while injections of soluble IL-2 did not. CONCLUSIONS/INTERPRETATION: Hydrogel delivery may reduce the number of injections required in IL-2 treatment protocols for autoimmune diabetes. Graphical abstract.
引用
- Nagy N, Kaber G, Kratochvil MJ, et al. Weekly injection of IL-2 using an injectable hydrogel reduces autoimmune diabetes incidence in NOD mice. Diabetologia. 2020. PMID: 33125521. doi:10.1007/s00125-020-05314-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。